Srdan Verstovek, MD, PhD, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the long-term follow-up results of a phase III trial (NCT01949805) and extension study of ropeginterferon alfa-2b compared to standard cytoreductive therapy in polycythemia vera (PV). Ropeginterferon alfa-2b is a novel long-acting interferon, with a pharmacokinetic profile that offers improved tolerability, which can selectively target malignant clones. A high rate of sustained molecular response was observed in the ropeg treated patients. This treatment achieves deep and durable responses, making disease progression rare with long-term treatment. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

свернуть